Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) reported revenues of $700,000 (down 73% YoY) in Q4 2020 from licenses and awards. Its revenues for 2020 are declined by...
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) generated $700,000 from its licenses and awards in Q4 2020. Its operating expenses declined marginally to $21.5 million in Q4 2020....
Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) has announced its baseline patient disease characteristics and demographics in the Phase 2b lenabasum study in cystic fibrosis. The company has also...